Variable Hematoloji / Transfüzyon Tıbbı

Blood Group Antigens, Compatibility Testing, and Alloimmunization

The foundation of transfusion safety is the accurate determination of the patient’s blood group and any antibodies previously developed. COMPATIBILITY TESTING consists of three stages:

ABO/Rh TYPING, ANTIBODY SCREENING (indirect Coombs), and CROSSMATCHING. ABO incompatibility leads to ACUTE HEMOLYTIC REACTION due to naturally occurring antibodies, and almost all cases of this condition result from SAMPLE/PATIENT IDENTIFICATION ERRORS; that is, it is more a PROCESS ERROR than a laboratory issue, and it is prevented by bedside identity verification.

Antibodies developed against non-ABO antigens (Rh, Kell, Duffy, Kidd, and others) are ACQUIRED through transfusion or pregnancy; this is called ALLOIMMUNIZATION. These antibodies can decrease over time to undetectable levels but rise rapidly upon re-exposure; the resulting condition is a DELAYED HEMOLYTIC TRANSFUSION REACTION, seen days after transfusion as unexplained hemoglobin drop and jaundice.

Therefore, the patient’s ANTIBODY HISTORY should be recorded even in a single center, and the patient should CARRY this information. In patients receiving multiple transfusions (sickle cell disease, thalassemia), extended antigen matching is considered to PREVENT ALLOIMMUNIZATION.

HLA alloimmunization is the main immune cause of PLATELET REFRACTORINESS.

Rapid management

Pre-transfusion COMPATIBILITY TESTING is in three stages:
ABO/Rh TYPING + ANTIBODY SCREENING (indirect Coombs) + CROSSMATCHING.
ABO INCOMPATIBILITY leads to acute hemolytic reaction and almost all cases are due to SAMPLE LABELING or PATIENT IDENTIFICATION ERRORS — this is a PROCESS problem, not a laboratory issue, and is prevented by bedside identification verification; URGENCY PRESSURE should not bypass this step.
If ANTIBODY SCREENING is POSITIVE, finding compatible blood TAKES TIME; for patients needing emergency transfusion, early communication with the blood bank is necessary.
ASK and RECORD THE PATIENT'S ANTIBODY HISTORY: antibodies may decrease to undetectable levels over time but rise rapidly upon re-exposure; if this information is lost, DELAYED HEMOLYTIC REACTION occurs.
UNEXPLAINED hemoglobin drop, jaundice, fever, and dark urine DAYS AFTER TRANSFUSION → DELAYED HEMOLYTIC TRANSFUSION REACTION; direct Coombs and antibody screening should be repeated.
In patients who RECEIVE MULTIPLE TRANSFUSIONS (SICKLE CELL, THALASSEMIA), extended antigen matching reduces alloimmunization.
PLATELET TRANSFUSION NON-RESPONSIVENESS → first evaluate clinical causes (fever, sepsis, bleeding, splenomegaly, medications), then assess HLA ALLOIMMUNIZATION.
Rh(D) NEGATIVE mother during PREGNANCY → anti-D prophylaxis.

Drug	Adult	Pediatric	Route	Duration
Pre-transfusion compatibility testing Compatibility testing answers three separate questions. ABO/Rh grouping determines the patient’s own antigens; this stage is fundamental for transfusion safety because the ABO system is the only system with naturally occurring strong antibodies, and incompatibility causes rapid, severe hemolysis. Antibody screening searches for non-ABO antibodies that the patient has developed previously through transfusion or pregnancy; if positive, it is determined which antigen the antibody reacts against, and a product that does not carry that antigen is selected. Crossmatching directly tests for incompatibility between the selected product and the patient’s serum. The weakest link in these three stages is not the laboratory but the sample collection process: a tube taken from the wrong patient or improperly labeled can have fatal consequences even in a perfectly functioning laboratory. Therefore, the sample must be labeled at the patient’s bedside, and identity verification must be repeated before the product is administered.	ABO/Rh typing, ANTIBODY SCREENING (indirect antiglobulin/Coombs test) and CROSSMATCHING are performed. When samples are taken, BED-SIDE PATIENT IDENTIFICATION is verified and the tube is labeled at the bedside; identity verification is REPEATED before attaching the product	The same process applies to children; in newborns, due to maternal antibodies, test interpretation is different and is carried out according to the pediatric transfusion protocol	—	Before every transfusion (sample validity period according to institutional protocol)
Approach in a patient with a positive antibody screen A positive antibody screen does not mean that a transfusion cannot be performed, but it significantly prolongs the preparation time. Once it is determined which antigen the antibody is against, donors who do not carry that antigen should be screened; because some antigens are common in the population, it can be difficult to find a suitable product, and in rare phenotypes, national or international blood banks may need to be contacted. The clinical implication of this fact is as follows: in patients planned for elective procedures where transfusion is anticipated, compatibility testing should be requested early; leaving the test until the day of the procedure leads to delaying the procedure in case of antibody positivity. In emergencies, early and transparent communication with the blood bank is critical; sharing the clinical urgency allows planning the course of action together until a suitable product is found (such as selecting the most compatible product or administering an incompatible product with physician approval).	The specificity of the antibody is determined, and a product that DOES NOT carry the relevant antigen is selected; this process TAKES TIME, and finding a suitable product for rare antibodies may take days. In a patient requiring emergency transfusion, EARLY COMMUNICATION with the BLOOD BANK is established, and the clinical urgency is shared.	The same principles apply	—	Until a suitable product is provided
Delayed hemolytic transfusion reaction Delayed hemolytic transfusion reaction is a direct result of alloimmunization and its mechanism is instructive. The patient has previously encountered a foreign erythrocyte antigen through transfusion or pregnancy and has developed an antibody; however, over time, the level of this antibody falls to undetectable levels and is not detected in antibody screening. When a product carrying the same antigen is given again, the memory response is activated, the antibody level rises rapidly, and the transfused erythrocytes are destroyed within days. The clinical presentation is subtle and therefore often overlooked: the patient fails to show the expected hemoglobin increase or experiences a drop in hemoglobin days after transfusion; jaundice, mild fever, and darkening of urine may accompany. If the transfusion-related connection is not recognized, the patient is transfused again and the cycle continues. This scenario is particularly dangerous in sickle cell patients because it can be mistaken for a painful crisis and may progress to hyperhemolysis syndrome.	In cases of unexplained hemoglobin decrease, jaundice, fever, darkening of urine, or failure to achieve the expected hemoglobin increase DAYS-WEEKS after transfusion: DIRECT COOMBS, antibody screening, lactate dehydrogenase, haptoglobin, bilirubin, and reticulocyte counts are evaluated; the blood bank is INFORMED	The same approach; in children, hemoglobin decrease creates clinical effects more quickly	—	Diagnostic evaluation
Prevention of alloimmunization and antibody card The loss of antibody knowledge is one of the most tangible systemic problems in transfusion medicine. An antibody detected in a patient can decrease to undetectable levels years later; when the patient goes to another center, the antibody screening comes back negative, and inappropriate products are given. Therefore, the information should travel with the patient; a written antibody card is simple but highly effective, and the importance of this card should be clearly explained to the patient. On the prevention side, the most effective approach is to ensure extended antigen matching in patients expected to receive numerous transfusions. Sickle cell disease holds a special place in this regard: patients receive numerous transfusions throughout their lives, and the difference in antigen distribution between the donor population and the patient population increases the risk of alloimmunization. Therefore, it is recommended that patients to be included in a chronic transfusion program undergo extended antigen typing before starting transfusion; if done later, interpretation becomes difficult due to products already given.	Every detected antibody is recorded PERMANENTLY and the patient is given a WRITTEN ANTIBODY CARD; the patient should show this card at every visit. In patients receiving MULTIPLE TRANSFUSIONS (SICKLE CELL DISEASE, THALASSEMIA), the use of extended antigen-compatible products is considered; SCOPE AND APPLICATION must be verified from the institutional transfusion protocol	In children to be enrolled in a chronic transfusion program, extended antigen typing should be performed BEFORE STARTING TRANSFUSION	—	Lifetime
HLA alloimmunization and platelet refractoriness The most common causes of platelet transfusion non-responsiveness are clinical, not immune; fever, sepsis, active bleeding, splenomegaly, disseminated intravascular coagulation, and certain drugs rapidly consume the transfused platelets. Therefore, when refractoriness is detected, the first step is reviewing the clinical situation, not expensive immunological tests. Once clinical causes are excluded and non-responsiveness persists across consecutive transfusions, HLA alloimmunization should be considered; the patient has developed antibodies against foreign HLA antigens previously encountered and rapidly destroys the transfused platelets. In this case, providing HLA-matched platelets is necessary, but this process takes time and may not be possible at every center. The use of leukocyte-reduced products is effective in preventing HLA alloimmunization, and therefore it has become a standard practice for patients who will receive multiple transfusions.	In non-responsiveness to platelet transfusion, CLINICAL CAUSES are evaluated FIRST (fever, sepsis, active bleeding, splenomegaly, disseminated intravascular coagulation, drugs); once these are excluded, HLA antibodies are investigated, and if necessary, HLA-MATCHED platelets are provided (platelet transfusion protocol)	The same approach is valid	—	As long as refractoriness continues

Alternative

In cases of urgent and life-threatening bleeding, the transfusion of group O red blood cells and compatible plasma may be considered before the completion of compatibility testing; this decision and product selection are made according to the institutional massive transfusion protocol (relevant protocol).
Leukocyte-reduced products reduce HLA alloimmunization and febrile non-hemolytic reactions; in many centers, this is standard practice.
Irradiated products prevent transfusion-associated graft-versus-host disease and are mandatory in conditions such as severe immunodeficiency and the use of related donors in stem cell transplantation (relevant protocols).
Anti-D immunoglobulin prophylaxis in Rh(D) negative women during pregnancy and childbirth prevents hemolytic disease of the newborn; the timing of administration is determined according to the national protocol (relevant protocol).
Autoantibodies in autoimmune hemolytic anemia complicate compatibility testing; in these patients, the selection of the 'most compatible' product and the sharing of clinical urgency with the blood bank is necessary (relevant protocol).
In patients with rare blood group phenotypes, frozen rare red cell stocks and the national blood bank network can be used; planned procedures in these patients should be coordinated in advance.

Red flags

SAMPLE LABELING or PATIENT IDENTIFICATION ERROR → ACUTE HEMOLYTIC REACTION due to ABO incompatibility; almost all of these reactions result from this process error and can be FATAL.
Fever, chills, back/flank pain, darkening of urine, hypotension during transfusion → ACUTE HEMOLYTIC REACTION; the transfusion must be STOPPED IMMEDIATELY (relevant protocol).
UNEXPLAINED hemoglobin decrease, jaundice, or failure to achieve expected increase DAYS AFTER transfusion → DELAYED HEMOLYTIC TRANSFUSION REACTION; often overlooked because it has a mild course.
Pain and hemoglobin drop after transfusion in patients with sickle cell disease → delayed hemolytic reaction can be MISSED as a painful crisis and may progress to HYPERHEMOLYSIS syndrome; additional transfusion can worsen the condition.
Failure to record the patient's ANTIBODY HISTORY or provide the patient with a card → antibodies may drop to undetectable levels over time, screening may be negative at another center, and incompatible products may be given.
Compatibility testing left to the day of an elective procedure → finding an appropriate product in case of antibody positivity may take DAYS and the procedure may be postponed.
In platelet refractoriness, directly targeting HLA antibodies → the most common causes are CLINICAL (fever, sepsis, bleeding, splenomegaly, drugs) and these should be evaluated first.
In a patient to be included in a chronic transfusion program, performing extended antigen typing AFTER transfusion → interpretation becomes difficult due to the products given; typing should be done BEFORE.
Skipping at-bedside patient identification under urgency pressure → is the main cause of the most fatal transfusion errors.

Disposition and follow-up

Green zone: Antibody screen negative, patient scheduled for elective transfusion: standard compatibility test, bedside patient identification, monitoring during transfusion, recording of results.
Yellow zone: Antibody screen positive, rare phenotype, heavily transfused patient, or suspected delayed hemolytic reaction: early contact with the blood bank, advanced immunohematologic evaluation, pre-planning of transfusion, arranging an antibody card.
Red zone: Acute hemolytic reaction, emergency transfusion requirement in massive bleeding, hyperhemolysis syndrome or life-threatening anemia with no suitable product: urgent management, immediate cessation of transfusion (in hemolytic reaction), simultaneous management with blood bank and hematology.

Key clinical points

READ FIRST — ABO error is a PROCESS, not a LABORATORY problem.

The ABO system is the only system with naturally occurring strong antibodies → incompatibility causes RAPID and SEVERE hemolysis | ALMOST ALL acute hemolytic reactions result from sample labeling or PATIENT IDENTIFICATION ERRORS | PRECAUTION: tube is labeled AT THE BEDSIDE, patient identification is RECHECKED before product administration | URGENCY PRESSURE should not bypass this step

The most deadly mistake in transfusion medicine arises from skipping the simplest step. The ABO system differs from other blood group systems in a fundamental way: a person naturally carries antibodies against ABO antigens they do not have, even if they have never encountered them. These antibodies are strong and rapidly destroy incompatible erythrocytes in the bloodstream; the resulting scenario can progress to shock, kidney failure, and widespread intravascular coagulation within minutes. Therefore, ABO compatibility is an absolute requirement. The critical observation here is this: modern laboratories perform ABO grouping almost flawlessly, so the vast majority of acute hemolytic reactions arise not from laboratory error but from process error. A tube taken from the wrong patient, a sample labeled with the correct patient's name, or a product given to the wrong patient can lead to disaster even in a perfectly functioning system. The context in which these errors most frequently occur is emergency situations; in rushed circumstances, identity verification is skipped. However, urgency is the reason for more careful implementation, not for skipping this step.

READ FIRST — delayed hemolytic reaction: silent and often overlooked

MECHANISM: antibodies developed from previous transfusion/pregnancy drop over time to UNDETECTABLE levels → screening comes out NEGATIVE → when the same antigen is given again, MEMORY RESPONSE rises rapidly → erythrocytes destroyed over DAYS | CLINICAL: drop in hemoglobin days after transfusion, failure to achieve expected increase, jaundice, mild fever, dark urine | DIAGNOSIS: DIRECT COOMBS + repetition of antibody screening

This table is a clinical result of immunological memory and for exactly this reason, it is difficult to prevent. The decrease in antibody levels over time is a normal process; the problem is that the declining antibody may not be visible in a screening test while immune memory is preserved. When the patient encounters the same antigen again, the response is rapid and strong. The clinical picture being subtle delays the diagnosis: the patient appears well days after the transfusion, only their hemoglobin has not increased as expected or has fallen again. This finding is often interpreted as 'insufficient transfusion' or 'continuing bleeding,' and the patient is transfused again; this creates a cycle that fuels hemolysis. In patients with sickle cell disease, the situation is particularly dangerous because hemolysis and pain are mixed with a painful crisis; moreover, in hyperhemolysis syndrome, the patient's own erythrocytes are also destroyed, so additional transfusion can worsen the picture. Therefore, this diagnosis should be considered in unexplained post-transfusion hemoglobin drops, and the blood bank should be informed.

READ FIRST — antibody information MUST BE CARRIED with the patient.

The detected antibody should be recorded as PERMANENT and the patient should be given a WRITTEN ANTIBODY CARD | Reason: antibody levels fall to UNMEASURABLE levels over the years → screening at another center comes out NEGATIVE → inappropriate product is given | Patients should show this card at EVERY VISIT | It is a simple, cheap, and HIGHLY EFFECTIVE precaution.

This recommendation is more about system design than medical knowledge, and for exactly this reason, it is often neglected. An antibody detected at one center remains in that center's records; when the patient goes to another hospital, another city, or returns to the same hospital years later, this information may not be accessible. Since the antibody itself falls to an unmeasurable level over time, newly conducted screening also comes out negative, and the patient's alloimmunization is not recognized. The result is a preventable delayed hemolytic reaction. The solution is to link the information to the patient rather than the institution: a written antibody card moves with the patient and is not affected by changing centers. As important as giving the card to the patient is to explain its importance; if the patient does not understand what the card is for, they will not carry or show it. Similarly, asking the patient before transfusion, 'Have you previously experienced blood incompatibility or problems during a blood transfusion? Were you given a card?' can reveal information not found in the records.

What is the purpose of the three stages of the compatibility test?

1) ABO/Rh TYPING → the patient's own antigens; ABO requires absolute compatibility | 2) ANTIBODY SCREENING (indirect Coombs) → previously acquired non-ABO antibodies from transfusion/pregnancy (Rh, Kell, Duffy, Kidd, etc.) | 3) CROSSMATCH → direct incompatibility testing between the selected product and the patient's serum | POSITIVE SCREENING = finding a suitable product TAKES TIME

Each of the three steps answers a different question and does not replace the others. ABO/Rh typing is the most basic and quick step; ABO incompatibility must be absolutely prevented due to natural antibodies. Antibody screening looks for acquired antibodies; these antibodies are found only in individuals who have previously encountered foreign erythrocytes, i.e., patients who have had transfusions or pregnancies. Therefore, screening in a man who has never had a transfusion and has never been pregnant is almost always negative, whereas the likelihood of positivity increases significantly in patients with multiple transfusions. Crossmatching adds a final safety layer by directly testing the suitability of the selected product for that patient. The most important practical clinical outcome is that a positive screening prolongs the preparation time. Therefore, in elective procedures where transfusion is anticipated, compatibility testing should not be left to the day of the procedure but should be requested in advance.

Preventing alloimmunization: in whom, how?

HIGH RISK: SICKLE CELL DISEASE, THALASSEMIA, patients in chronic transfusion programs, women with multiple pregnancies | PRECAUTION: EXTENDED ANTIGEN MATCHING (scope according to institutional protocol) and LEUKOCYTE-REDUCED product | TIMING: extended antigen typing should be done BEFORE STARTING TRANSFUSION — if done later, interpretation is complicated due to the products already given

The risk of alloimmunization increases with the number of transfusions received and the difference in antigen distribution between donor and recipient populations. Sickle cell disease is a classic example where these two factors come together: patients receive numerous transfusions throughout their lifetime, and in some communities, the antigen distribution of the donor pool differs from that of the patient population; as a result, the frequency of alloimmunization is high. Patients with thalassemia and other chronic transfusion program patients carry a similar risk. Matching for specific antigens beyond the basic blood group in these patients significantly reduces alloimmunization; which antigens are included is determined by institutional protocol. The most critical detail in practice is timing: extended antigen typing should be done before the patient has received any transfusions. Typing performed after a transfusion gives mixed results because donor erythrocytes are circulating, and the patient’s true phenotype cannot be determined. Therefore, typing should be planned before the first transfusion for every patient to be enrolled in a chronic transfusion program.

Featured external sources

Pretransfusion Testing review.Identification verification, ABO/RhD, antibody screening, and crossmatching.
JPAC Red Book chapter 13.Red cell immunohematology and compatibility testing.
ASH sickle cell transfusion support guideline.Phenotype/genotype, antigen matching, and alloimmunization in sickle cell disease.
AABB Circular of Information.Current official product information for the safe administration of blood products.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

The foundation of transfusion safety is the accurate determination of the patient’s blood group and any previously developed antibodies. Compatibility testing consists of three stages, each answering a different question:

ABO/Rh grouping determines the patient’s own antigens, antibody screening searches for previously acquired non-ABO antibodies, and crossmatching directly tests for incompatibility between the selected product and the patient’s serum. The ABO system differs from others in a fundamental point: even if a person has never encountered them, they naturally carry antibodies against ABO antigens they do not have.

These antibodies are strong and can rapidly destroy incompatible erythrocytes in the bloodstream, causing shock, renal failure, and widespread intravascular coagulation within minutes. Modern laboratories perform ABO grouping almost flawlessly, so the majority of acute hemolytic reactions arise not from laboratory error but from sample labeling and patient identification mistakes; in other words, this is a process issue and can be prevented by patient identity verification at the bedside.

Antibodies against non-ABO antigens are acquired through transfusion or pregnancy; this is called alloimmunization. An important feature of these antibodies is that they decrease to an immeasurable level over time, but immune memory is preserved.

When the same antigen is reintroduced, the memory response is quickly activated and the given erythrocytes are destroyed within days; The resulting picture is a delayed hemolytic transfusion reaction. The clinical presentation is faint: failure to achieve the expected hemoglobin increase or relapse in hemoglobin days after transfusion, jaundice and mild fever are observed.

For this reason, the patient's antibody history should be permanently recorded and the patient should be given a written antibody card. Extended antigen matching in patients receiving multiple transfusions reduces alloimmunization and this typing should be done prior to initiation of transfusion.

HLA alloimmunization is the main immune cause of platelet refractoriness, but the most common causes of refractoriness are clinical and should be evaluated first.

Differential diagnosis and assessment

Key considerations

Fever during transfusion: febrile nonhemolytic reaction, acute hemolytic reaction, bacterial contamination and fever due to underlying disease should be distinguished (protocols involved).
Failure to achieve hemoglobin increase after transfusion: Sustained bleeding, delayed hemolytic transfusion reaction, hemodilution, hypersplenism, and autoimmune hemolysis should be considered.
Post-transfusion respiratory distress: transfusion-associated acute lung injury, volume overload, anaphylaxis, and underlying heart-lung disease should be distinguished (protocol involved).
Post-transfusion pain and anemia in sickle cell disease: painful crisis, delayed hemolytic reaction, and hyperhemolysis syndrome should be distinguished; Additional transfusion may be harmful in hyperhemolysis (protocols involved).
Direct Coombs positivity: delayed hemolytic transfusion reaction, autoimmune hemolytic anemia, drug-associated immune hemolysis, and passive antibody transfer (intravenous immunoglobulin, anti-D) should be distinguished (relevant protocol).
Unresponsiveness to platelet transfusion: clinical causes (fever, sepsis, hemorrhage, splenomegaly, disseminated intravascular coagulation, drugs) and immune causes (HLA and platelet-specific antibodies) should be distinguished (relevant protocol).
Difficulty in eligibility testing: autoimmune hemolytic anemia-induced autoantibodies, multiple alloantibodies, and rare phenotypes should be evaluated; Clinical urgency should be shared with the blood bank.

Clinical decision reasoning

Why it matters

The subject of this protocol is an area where medical knowledge alone is not sufficient and where system design directly saves lives. Acute hemolytic transfusion reaction is the clearest example of this.

The biology of the disease is completely known, laboratory tests are reliable, and when the correct product is selected, the reaction does not occur; yet these reactions still happen. The reason is almost always the same: a sample taken from the wrong patient, a tube incorrectly labeled, or a product given to the wrong patient.

In other words, the problem is not in the knowledge but in the process. The practical implication of this observation is that bedside patient identification should be seen as a vital step, not a formality.

It is also noteworthy that this step is most frequently skipped in emergency contexts; yet an error made in an emergency patient is less forgiving than one made in an elective patient because the patient is already fragile. Delayed hemolytic transfusion reaction, on the other hand, carries a different lesson: a negative test result does not mean that the condition is absent.

Antibody screening only shows antibodies at a measurable level; an antibody that has declined over time will not appear in the screening test, but the immune memory remains intact. Therefore, the inference of 'screening negative, no problem' is incorrect in a previously alloimmunized patient.

The way to close this blind spot in the system is not through the laboratory but through record-keeping; the detected antibody must be permanently recorded and, more importantly, the information must travel with the patient. A written antibody card is a low-cost and high-impact solution; however, if its importance is not explained to the patient, it will not be carried and will be useless.

Similarly, asking the patient about past incompatibility before transfusion can reveal information that is not present in the records. The fact that delayed reactions are clinically subtle should also be emphasized.

The patient does not present a dramatic picture; only their hemoglobin has not risen as expected. When this finding is not associated with the transfusion, it is interpreted as 'inadequate transfusion' or 'ongoing bleeding,' and the patient is transfused again.

This establishes a cycle that feeds hemolysis. In patients with sickle cell disease, this cycle is particularly dangerous; in hyperhemolysis syndrome, the patient's own erythrocytes are also destroyed, so additional transfusion worsens the situation, and because it is counterintuitive, it is recognized late.

On the prevention side, the timing of extended antigen matching contains an instructive detail. Typing should be done before the patient has received any transfusion; because the patient's true phenotype cannot be determined when donor erythrocytes are circulating.

This is a concrete application of the principle 'requesting the right test at the right time' and should be planned for patients who will be enrolled in a chronic transfusion program before their first transfusion. Finally, the recommendation to first evaluate clinical causes in platelet refractoriness is an example of probability-based thinking.

HLA alloimmunization is a real and significant cause, but fever, sepsis, bleeding, and splenomegaly are much more common and mostly correctable. Reviewing these causes before turning to expensive and time-consuming immunological tests is both a faster and more efficient approach.

Safety and monitoring

Complications and safety

Critical complications

Acute hemolytic reaction due to ABO incompatibility can result in intravascular hemolysis, shock, acute kidney injury, disseminated intravascular coagulation, and death.
Delayed hemolytic transfusion reaction leads to a drop in hemoglobin, increased transfusion requirements, and delayed diagnosis.
Hyperhemolysis syndrome may develop in patients with sickle cell disease; in this scenario, additional transfusion worsens hemolysis and is life-threatening.
Alloimmunization makes finding compatible blood more difficult in the future and may cause elective procedures to be postponed.
HLA alloimmunization leads to platelet refractoriness and an increased risk of bleeding.
Loss of antibody knowledge causes preventable hemolytic reactions in different centers.
Alloimmunization in Rh(D) negative women leads to hemolytic disease of the newborn in subsequent pregnancies (relevant protocol).
Delayed requesting of the compatibility test causes elective surgeries and procedures to be postponed.

Special patient populations

Special considerations

Sickle cell patients: the risk of alloimmunization is high, extended antigen matching is recommended, and special attention is required regarding delayed hemolytic reaction and hyperhemolysis syndrome (relevant protocols).
Patients with thalassemia and in the chronic transfusion program: extended antigen typing should be done before the first transfusion, and an antibody card should be arranged (relevant protocol).
Women with multiple pregnancies: alloantibodies acquired during pregnancy may be present; history should be questioned before transfusion.
Rh(D) negative women of reproductive age: Rh(D) negative products should be used whenever possible, and anti-D prophylaxis should be planned during pregnancy (relevant protocol).
Patients with autoimmune hemolytic anemia: autoantibodies complicate compatibility testing; selection of the "most compatible" product and close communication with the blood bank are required (relevant protocol).
Hematopoietic stem cell transplant recipients: product selection changes periodically in ABO incompatible transplants and is done according to the transplant center protocol; irradiated products are mandatory (relevant protocols).
Patients with immunodeficiency: irradiated and, if necessary, cytomegalovirus-safe products should be used (relevant protocol).
Newborns: test interpretation differs due to maternal antibodies, and the pediatric transfusion protocol is applied (relevant protocol).

Follow-up and reassessment

Follow-up plan

Monitoring in transfused patients is not limited to the procedure itself. The patient should be closely monitored during transfusion and assessed for fever, chills, back and flank pain, hypotension, and changes in urine color; if these findings occur, the transfusion should be stopped immediately and the acute reaction protocol applied.

After transfusion, it should be documented whether the expected increase in hemoglobin or platelets has been achieved; this simple step allows early detection of both delayed hemolytic reactions and platelet refractoriness. In cases where the expected increase is not achieved, ongoing bleeding and clinical causes should be assessed first, followed by immunological causes.

In patients developing unexplained decreases in hemoglobin, jaundice, or darkening of urine in the days following transfusion, delayed hemolytic transfusion reaction should be considered; direct Coombs test and antibody screening should be repeated, and the blood bank should be informed. This notification is necessary not only for that patient but also for the safety of subsequent transfusions.

Every detected alloantibody should be permanently recorded, and a written antibody card should be issued to the patient. The patient should be clearly informed about what this card means, why it needs to be kept, and why it should be shown at every visit; if the importance of the card is not explained, it becomes ineffective and loses its function.

In patients receiving frequent transfusions, antibody screening should be repeated regularly, and newly developed antibodies should be recorded. In patients on a chronic transfusion program, extended antigen matching should be maintained, and monitoring should be planned in terms of iron load.

For patients scheduled for elective surgery or procedures, compatibility testing should not be left to the day of the procedure; especially in patients known to have been previously alloimmunized, early communication with the blood bank should be established to ensure the appropriate product is prepared in advance. A common principle valid for the entire team is that bedside patient identification must never be skipped; this step is particularly at risk in emergencies and during handovers and should be supported by institutional audit processes.